United Therapeutics Corporation (UTHR) EPS Estimated At $3.51

April 24, 2018 - By Richard Conner

United Therapeutics Corporation (NASDAQ:UTHR) LogoInvestors sentiment increased to 1.14 in Q4 2017. Its up 0.15, from 0.99 in 2017Q3. It increased, as 26 investors sold United Therapeutics Corporation shares while 112 reduced holdings. 53 funds opened positions while 105 raised stakes. 40.90 million shares or 1.42% less from 41.49 million shares in 2017Q3 were reported.
Invesco invested in 0.02% or 281,449 shares. Moreover, Fil Ltd has 0.26% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 641,675 shares. Amp Cap Ltd invested in 69,837 shares or 0.06% of the stock. Tobam accumulated 32,243 shares. Thrivent Finance For Lutherans, a Minnesota-based fund reported 9,331 shares. Riverhead Management Limited Liability Co has 0.05% invested in United Therapeutics Corporation (NASDAQ:UTHR). Old Mutual (Uk) Ltd reported 1.28% stake. Price T Rowe Assoc Md reported 0% stake. Alliancebernstein Ltd Partnership stated it has 0% in United Therapeutics Corporation (NASDAQ:UTHR). Parametric Portfolio Associates Ltd, Washington-based fund reported 175,100 shares. Glob X Management Ltd Llc, New York-based fund reported 257 shares. Oakworth Cap reported 64 shares. Bancshares Of Montreal Can reported 107,039 shares. Creative Planning stated it has 0% in United Therapeutics Corporation (NASDAQ:UTHR). Fdx Inc has 0.02% invested in United Therapeutics Corporation (NASDAQ:UTHR) for 4,345 shares.

Since October 26, 2017, it had 0 insider buys, and 10 selling transactions for $26.79 million activity.

Analysts expect United Therapeutics Corporation (NASDAQ:UTHR) to report $3.51 EPS on April, 25.They anticipate $0.38 EPS change or 9.77 % from last quarter’s $3.89 EPS. UTHR’s profit would be $151.79 million giving it 7.76 P/E if the $3.51 EPS is correct. After having $2.06 EPS previously, United Therapeutics Corporation’s analysts see 70.39 % EPS growth. The stock decreased 2.30% or $2.56 during the last trading session, reaching $108.94. About 127,930 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has declined 23.69% since April 24, 2017 and is downtrending. It has underperformed by 35.24% the S&P500.

United Therapeutics Corporation (NASDAQ:UTHR) Ratings Coverage

Among 5 analysts covering United Therapeutics (NASDAQ:UTHR), 1 have Buy rating, 1 Sell and 3 Hold. Therefore 20% are positive. United Therapeutics had 10 analyst reports since October 26, 2017 according to SRatingsIntel. Wedbush maintained it with “Buy” rating and $232.0 target in Thursday, January 4 report. The rating was upgraded by Credit Suisse on Tuesday, April 3 to “Neutral”. Barclays Capital maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Thursday, February 22. Barclays Capital has “Underweight” rating and $105 target. The firm has “Buy” rating by Wedbush given on Tuesday, February 27. H.C. Wainwright maintained it with “Hold” rating and $95.0 target in Thursday, October 26 report. Cowen & Co maintained the shares of UTHR in report on Thursday, October 26 with “Hold” rating. On Wednesday, December 27 the stock rating was maintained by Wedbush with “Buy”. Wedbush maintained United Therapeutics Corporation (NASDAQ:UTHR) rating on Monday, November 13. Wedbush has “Buy” rating and $213.0 target. The firm has “Underperform” rating by Credit Suisse given on Thursday, February 22.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $4.71 billion. The company's product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 11.7 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

United Therapeutics Corporation (NASDAQ:UTHR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: